文献速递食管与纵隔外科

胸段食管鳞癌淋巴结跳跃转移的预后评估

Prognostic Evaluation of Nodal Skip Metastasis for Thoracic Esophageal Squamous Cell Carcinoma.
PubMed 文献 · Ann Thorac Surg · 2019-04-27

该回顾性研究纳入2009年3月至2012年3月在四川大学华西医院胸外科行食管切除术的胸段食管鳞癌(ESCC)患者,评估淋巴结跳跃转移(NSM)的危险因素与预后价值。全队列NSM发生率为37.9%,肿瘤位置(P = .016)、pT分期(P = .029)和pN分期(P < .001)为NSM独立危险因素。NSM对总生存(OS)的影响主要体现在pN2患者(P = .001),NSM分层的预后价值主要体现在下胸段肿瘤患者(P = .013)。

要点

  • 全队列NSM发生率为37.9%,肿瘤位置、pT分期和pN分期为独立危险因素。
  • pN2患者中伴NSM者OS显著更差(P = .001),pN1患者中无显著差异。
  • 下胸段ESCC中NSM level 1者OS显著优于level 2者(P = .013)。

核心结论

  • NSM对胸段ESCC预后的影响可能主要体现在pN2分期患者中。
  • NSM分层的预后价值可能主要体现在下胸段肿瘤患者中。

研究设计与样本

  • 回顾性研究,纳入2009年3月至2012年3月四川大学华西医院胸外科行食管切除术的胸段ESCC患者。

主要发现

  • 全队列NSM发生率为37.9%。
  • 肿瘤位置(P = .016)、pT分期(P = .029)和pN分期(P < .001)为NSM独立危险因素。
  • 伴与不伴NSM患者的总生存(OS)相似。
  • pN1患者中伴与不伴NSM的OS无显著差异,pN2患者中伴NSM者OS显著更差(P = .001)。
  • NSM level 1与level 2患者OS相似,但下胸段ESCC中level 1者OS显著优于level 2者(P = .013)。

临床怎么用

  • 对pN2期胸段ESCC患者应关注NSM状态以辅助预后评估。
  • 下胸段ESCC患者可关注NSM分层(level 1 vs level 2)以辅助预后判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nodal skip metastasis (NSM) is a prognostic factor in certain malignant tumors, but the clinical and prognostic implications of NSM in esophageal squamous cell carcinoma (ESCC) are still unclear. The study aimed to assess its risk factors and prognostic value in thoracic ESCC. METHODS: A retrospective study was conducted in patients with thoracic ESCC who underwent esophagectomy from March 2009 to March 2012 in the Department of Thoracic Surgery, West China Hospital, Sichuan University. The prognostic implications and risk factors of NSM were assessed in our study. RESULTS: The incidence of NSM in the entire cohort was 37.9%. Tumor location (P = .016), pT stage (P = .029), and pN stage (P < .001) were identified to be independent risk factors for NSM. The overall survival (OS) was similar between patients with and without NSM. The OS had no significant difference between pN1 patients with and without NSM, whereas the OS was significantly worse in pN2 patients with NSM than those without NSM (P = .001). The OS was similar between patients with NSM level 1 and NSM level 2, but the OS was significantly better in patients with NSM level 1 than NSM level 2 among patients with lower thoracic ESCC (P = .013). CONCLUSIONS: The effect of NSM on prognosis of thoracic ESCC may be mainly reflected in patients with pN2 stage. The prognostic value of NSM level for thoracic ESCC may be mainly reflected in patients with lower thoracic tumor.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. He SL, Yang YS, Wang WP, et al. Prognostic Evaluation of Nodal Skip Metastasis for Thoracic Esophageal Squamous Cell Carcinoma. Ann Thorac Surg. 2019. PMID: 31039351. doi:10.1016/j.athoracsur.2019.03.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。